Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer

Chieh Chien Lee, Hui Yi Shiao, Wen Chieh Wang, Hsing Pang Hsieh

研究成果: Review article同行評審

40 引文 斯高帕斯(Scopus)


Introduction: EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreatic cancer. Numerous drugs have been developed in order to target the tyrosine domain of EGFR as an approach in cancer treatment.Areas covered: This article focuses on the different generations of EGFR tyrosine kinase inhibitors (TKIs). This spans from the emergence of the first-generation EGFR-TKIs to overcoming drug resistance using second-generation EGFR-TKIs and to reducing adverse effect (AE) using mutant-selective third-generation EGFR-TKIs.Expert opinion: Current TKI treatment is frequently accompanied by drug resistance and/or serious AEs. There has been the promise of advancements in second-generation EGFR-TKIs that could overcome drug resistance, acting as second- or third-line salvage treatment, but this promise has yet to be met. That being said, both issues are currently being addressed with mutant-selective EGFR-TKIs with the expectation of bringing more EGFR-targeted therapy into the next phase of cancer therapy in the future.

頁(從 - 到)1333-1348
期刊Expert Opinion on Investigational Drugs
出版狀態Published - 2014 十月 1

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

指紋 深入研究「Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer」主題。共同形成了獨特的指紋。